1. P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INFORMED BY CLINICAL BIOMARKER DATA FROM VERUBECESTAT AND OTHER BACE INHIBITORS. (1st July 2019) Authors: Rasmussen, Christian; Kleijn, Huub Jan; Kalinina, Juliya; Dockendorf, Marissa; Savage, Mary J.; Struyk, Arie; Forman, Mark; Stone, Julie A. Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7(2019)Part 11 Page Start: P571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects. Issue 5 (19th June 2019) Authors: Forman, Mark; Palcza, John; Tseng, Jack; Stone, Julie A.; Walker, Brittany; Swearingen, Dennis; Troyer, Matthew D.; Dockendorf, Marissa F. Journal: Clinical and translational science Issue: Volume 12:Issue 5(2019) Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗